share_log

Clene | 10-K: Annual report

Clene | 10-K: Annual report

Clene | 10-K：年度报表
美股sec公告 ·  03/13 07:53
Moomoo AI 已提取核心信息
Clene Inc., a clinical-stage pharmaceutical company, reported its annual financial results, highlighting a 38% increase in total revenue from $473,000 in 2022 to $654,000 in 2023. This growth was driven by a 51% rise in product revenue and an 8% increase in royalty revenue. Despite this, the company experienced a 16% decrease in operating expenses, primarily due to reduced research and development costs, which fell from $31.92 million to $26.655 million. General and administrative expenses also decreased by 15%. However, Clene Inc. reported a net loss of $49.504 million, a 65% increase from the previous year's $29.918 million loss. The company has not yet achieved profitability and has no drugs approved for commercial sale. Clene Inc. continues to focus on developing its novel clean-surfaced nanotechnology (CSN®) therapeutics, with multiple drug assets in development and clinical trials, primarily for neurology applications. The company's future plans include initiating an international Phase 3 study of CNM-Au8 30 mg, RESTORE-ALS, in the second half of 2024, contingent upon funding, and further engagement with the FDA to support potential approval of their drug candidates.
Clene Inc., a clinical-stage pharmaceutical company, reported its annual financial results, highlighting a 38% increase in total revenue from $473,000 in 2022 to $654,000 in 2023. This growth was driven by a 51% rise in product revenue and an 8% increase in royalty revenue. Despite this, the company experienced a 16% decrease in operating expenses, primarily due to reduced research and development costs, which fell from $31.92 million to $26.655 million. General and administrative expenses also decreased by 15%. However, Clene Inc. reported a net loss of $49.504 million, a 65% increase from the previous year's $29.918 million loss. The company has not yet achieved profitability and has no drugs approved for commercial sale. Clene Inc. continues to focus on developing its novel clean-surfaced nanotechnology (CSN®) therapeutics, with multiple drug assets in development and clinical trials, primarily for neurology applications. The company's future plans include initiating an international Phase 3 study of CNM-Au8 30 mg, RESTORE-ALS, in the second half of 2024, contingent upon funding, and further engagement with the FDA to support potential approval of their drug candidates.
临床阶段的制药公司Clene Inc. 公布了其年度财务业绩，强调总收入从2022年的47.3万美元增长了38％，增至2023年的65.4万美元。这一增长是由产品收入增长51％和特许权使用费收入增长8％推动的。尽管如此，该公司的运营费用下降了16％，这主要是由于研发成本的降低，从3192万美元降至2665.5万美元。一般和管理费用也下降了15％。但是，Clene Inc.公布的净亏损为4,9504万美元，较上一年的2991.8万美元亏损增长了65％。该公司尚未实现盈利，也没有获准商业销售的药物。Clene Inc. 继续专注于开发其新型的清洁表面纳米技术（CSN®）疗法，有多种药物资产正在开发和临床试验中，主要用于神经病学应用。该公司的未来计划包括在2024年下半年启动一项针对CNM-Au8 30 mg（RESTORE-ALS）的3期国际研究，视资金而定，以及进一步与美国食品药品管理局合作以支持其候选药物的潜在批准。
临床阶段的制药公司Clene Inc. 公布了其年度财务业绩，强调总收入从2022年的47.3万美元增长了38％，增至2023年的65.4万美元。这一增长是由产品收入增长51％和特许权使用费收入增长8％推动的。尽管如此，该公司的运营费用下降了16％，这主要是由于研发成本的降低，从3192万美元降至2665.5万美元。一般和管理费用也下降了15％。但是，Clene Inc.公布的净亏损为4,9504万美元，较上一年的2991.8万美元亏损增长了65％。该公司尚未实现盈利，也没有获准商业销售的药物。Clene Inc. 继续专注于开发其新型的清洁表面纳米技术（CSN®）疗法，有多种药物资产正在开发和临床试验中，主要用于神经病学应用。该公司的未来计划包括在2024年下半年启动一项针对CNM-Au8 30 mg（RESTORE-ALS）的3期国际研究，视资金而定，以及进一步与美国食品药品管理局合作以支持其候选药物的潜在批准。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

独立文件9  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息